DONG-A ST CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69,000 KRW | 0.00% |
|
+0.29% | -0.14% |
| Sales 2024 * | 646B 472M | Sales 2025 * | 687B 501M | Capitalization | 600B 438M |
|---|---|---|---|---|---|
| Net income 2024 * | 39B 28.47M | Net income 2025 * | 36B 26.28M | EV / Sales 2024 * | 1.13 x |
| Net Debt 2024 * | 127B 92.71M | Net Debt 2025 * | 105B 76.69M | EV / Sales 2025 * | 1.03 x |
| P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
17
x | Employees | 1,662 |
| Yield 2024 * |
1% | Yield 2025 * |
1.09% | Free-Float | 52.01% |
More Fundamentals
* Assessed data
More news
| 1 week | +0.29% | ||
| Current month | -6.88% | ||
| 1 month | -8.12% | ||
| 3 months | -1.15% | ||
| 6 months | +24.35% | ||
| Current year | -0.14% |
1 week
67 100.00
69 900.00
1 month
65 500.0077 200.00
Current year
64 200.0088 000.00
1 year
47 745.1088 000.00
3 years
45 271.0597 078.05
5 years
45 271.05114 859.67
10 years
45 271.05174 452.13
| Managers | Title | Age | Since |
|---|---|---|---|
Min-Young Kim
CEO | Chief Executive Officer | 52 | - |
Jae-Hong Park
PSD | President | 55 | - |
Seong-Geun Lee
BRD | Director/Board Member | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beom-Jun Kim
BRD | Director/Board Member | 50 | - |
Min-Young Kim
CEO | Chief Executive Officer | 52 | - |
Jae-Sang Ryu
BRD | Director/Board Member | 54 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.16% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 69,000 | 0.00% | 14,010 |
| 24-04-24 | 69,000 | +0.29% | 11,916 |
| 24-04-23 | 68,800 | -0.58% | 16,668 |
| 24-04-22 | 69,200 | +0.14% | 32,103 |
| 24-04-19 | 69,100 | +0.44% | 44,551 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.14% | 436M | |
| +4.16% | 70.78B | |
| +10.72% | 9.15B | |
| -17.03% | 4.84B | |
| +37.51% | 4.22B | |
| +3.92% | 3.92B | |
| +18.14% | 2.55B | |
| -24.13% | 2.26B | |
| -29.70% | 2.24B | |
| +9.09% | 1.92B |
- Stock Market
- Equities
- A170900 Stock
